Top

Published in:

01-10-2012 | Editorial

Growth hormone deficiency and cardiovascular risk: do we need additional markers?

Authors: M. Gola, A. Giustina

Published in: Endocrine | Issue 2/2012

Excerpt

Atherosclerosis, a chronic inflammatory disease of large and medium size arteries, continues to be the leading cause of cardiovascular events and one of the most common causes of mortality and cardiovascular disease [1]. Atherosclerotic lesion progression depends on chronic inflammation in the artery wall, and the innate and adaptive immune responses are involved in these processes [2]. In recent years, several new circulating markers, including C-reactive protein (CRP), fibrinogen, lipoprotein(a) (Lp(a)), and homocysteine [3‐5] have been proposed as potential risk factors for atherothrombotic vascular disease. …

V.L. Roger, A.S. Go, D.M. Lloyd-Jones et al., Executive summary: heart disease and stroke statistics—2011 update. A report from the American Heart Association. Circulation 123(4), e18–e209 (2011)PubMedCrossRef

G.K. Hansson, A. Hermansson, The immune system in atherosclerosis. Nat. Immunol. 12, 204–212 (2011)PubMedCrossRef

W. Xu, R. Li, S. Zhang, L. Gong, Z. Wang, W. Ren, C. Xia, Q. Li, The relationship between high-sensitivity C-reactive protein and ApoB, ApoB/ApoA1 ratio in general population of China. Endocrine (2012). doi:10.1007/s12020-012-9599-x

N.P. Kadoglou, G. Fotiadis, Z. Athanasiadou, I. Vitta, S. Lampropoulos, I.S. Vrabas, The effects of resistance training on ApoB/ApoA-I ratio, Lp(a) and inflammatory markers in patients with type 2 diabetes. Endocrine (2012). doi:10.1007/s12020-012-9650-y PubMed

C. Gazzaruso, A. Coppola, T. Montalcini, E. Baffero et al., Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus. Endocrine 41, 89–95 (2012)PubMedCrossRef

A.S. Bates, W. Van’t Hoff, P.J. Jones, R.N. Clayton, The effect of hypopituitarism on life expectancy. J. Clin. Endocrinol. Metab. 81, 1169–1172 (1996)PubMedCrossRef

T. Rosen, B.-A. Bengsston, Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336, 285–288 (1990)PubMedCrossRef

M. Bondanelli, M.R. Ambrosio, A. Onofri et al., Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome. J. Clin. Endocrinol. Metab. 91, 3928–3934 (2006)PubMedCrossRef

G.A. Laughlin, E. Barrett-Connor, M.H. Criqui et al., The prospective association of serum insulin like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J. Clin. Endocrinol. Metab. 89, 114–120 (2004)PubMedCrossRef

10.

A. Giustina, M. Licini, A.R. Bussi et al., Effects of sex and age on the growth hormone response to galanin in healthy human subjects. J. Clin. Endocrinol. Metab. 76, 1369–1372 (1993)PubMedCrossRef

11.

A. Giustina, W.B. Wehrenberg, Influence of thyroid hormones on the regulation of growth hormone secretion. Eur. J. Endocrinol. 133, 646–653 (1995)PubMedCrossRef

12.

V. Markussis, S.A. Beshyah, C. Fisher, K.H. Parker, A.N. Nicolaides, D.G. Johnston, Abnormal carotid arterial wall dynamics in symptom free hypopituitary adults. Eur. J. Endocrinol. 136, 157–164 (1997)PubMedCrossRef

13.

W.J. Brickman, B.L. Silverman, Cardiovascular effects of growth hormone. Endocrine 12, 153–161 (2000)PubMedCrossRef

14.

A. Colao, C. di Somma, R. Pivonello et al., The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. J. Clin. Endocrinol. Metab. 87, 1088–1093 (2002)PubMedCrossRef

15.

P. Maison, P. Chanson, Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 108, 2648–2652 (2003)PubMedCrossRef

16.

A. Giustina, Does growth hormone replacement therapy improve cardiac function? Nat. Clin. Pract. Endocrinol. Metab. 3, 614–615 (2007)PubMedCrossRef

17.

M. Andreassen, J. Frystyk, J. Faber, L.Ø. Kristensen, GH activity and markers of inflammation: a crossover study in healthy volunteers treated with GH and a GH receptor antagonist. Eur. J. Endocrinol. 166, 811–819 (2012)PubMedCrossRef

18.

M. Gola, S. Bonadonna, M. Doga, A. Giustina, Growth hormone and cardiovascular risk factors. J. Clin. Endocrinol. Metab. 90, 1864–1870 (2005)PubMedCrossRef

19.

W. Koenig, M. Sund, M. Frolich, H.G. Fischer, H. Lowel, A. Doring, C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 to 1992. Circulation 99, 237–242 (1999)PubMedCrossRef

20.

Emerging Risk Factors Collaboration, S. Kaptoge, E. Di Angelantonio, G. Lowe, M.B. Pepys, S.G. Thompson, R. Collins, J. Danesh, C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375, 132–140 (2010)PubMedCrossRef

21.

G. Sesmilo, B.M. Biller, J. Llevadot et al., Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann. Intern. Med. 133, 111–122 (2000)PubMed

22.

G. Sesmilo, K.K. Miller, D. Hayden, A. Klibanski, Inflammatory cardiovascular risk markers in women with hypopituitarism. J. Clin. Endocrinol. Metab. 86, 5774–5781 (2001)PubMedCrossRef

23.

L. Li, W. Ren, J. Li et al., Increase in serum pregnancy-associated plasma protein-A is correlated with increase in cardiovascular risk factors in adult patients with growth hormone deficiency. Endocrine (2012). doi:10.1007/s12020-012-9697-9

24.

J.L. Beaudeux, L. Burc, F. Imbert-Bismut et al., Serum plasma pregnancy-associated protein A: a potential marker of echogenic carotid atherosclerotic plaques in asymptomatic hyperlipidemic subjects at high cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 23, e7–e10 (2003)PubMedCrossRef

25.

C. Heeschen, S. Dimmeler, C.W. Hamm, S. Fichtlscherer, M.L. Simoons, A.M. Zeiher, CAPTURE Study Investigators, Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J. Am. Coll. Cardiol. 45, 229–237 (2005)PubMedCrossRef

26.

C. Joaquin, E. Aguilera, M.L. Granada et al., Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A. Eur. J. Endocrinol. 158(4), 483–490 (2008)PubMedCrossRef

27.

D. Deepak, C. Daousi, M. Javadpour, D. Clark, Y. Perry, J. Pinkney, I.A. Macfarlane, The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency. Growth Horm. IGF Res. 20, 220–225 (2010)PubMedCrossRef

28.

C.C. van Bunderen, I.C. van Nieuwpoort, L.I. Arwert et al., Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. J. Clin. Endocrinol. Metab. 96, 3151–3159 (2011)PubMedCrossRef

29.

H.J. Schneider, J. Klotsche, H.U. Wittchen, German KIMS board and of the DETECT study et al., Effects of growth hormone replacement within the KIMS survey on estimated cardiovascular risk and predictors of risk reduction in patients with growth hormone deficiency. Clin. Endocrinol. (Oxf) 75, 825–830 (2011)CrossRef

Title: Growth hormone deficiency and cardiovascular risk: do we need additional markers?
Authors: M. Gola
A. Giustina
Publication date: 01-10-2012
Publisher: Springer US
Published in: Endocrine / Issue 2/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-012-9769-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2012

The effects of fever on hormone ghrelins, immunoglobulins, and heat shock protein 70 expression after swine flu vaccinations

Genotype–phenotype correlation in Juvenile Paget disease: role of molecular alterations of the TNFRSF11B gene

Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism

Effects of prolonged exercise on agouti-related protein: a pilot study

The Lebanese allele at the LDLR in normocholesterolemic people merits reconsideration of genotype phenotype correlations in familial hypercholesterolemia

PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials